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Eortality in
atients With Atrial
ibrillation and Heart Failure
e read with interest the paper by Nieuwlaat et al. (1) on patients
ith atrial fibrillation (AF) and heart failure (HF) from the
bservational Euro Heart Survey. We have recently reported a
arge series of patients (n  1,269) with both AF and HF and a
imilar number of deaths (n  247) during follow-up (2).
The Euro Heart Survey was a declarative multicenter registry,
hereas we performed a single-center systematic continuous anal-
sis retrieving information from the computerized codification
ystem filled in for each patient using the International Classifi-
ation of Diseases-10th Revision of the World Health Organiza-
ion (3). It is interesting to note that in both studies the
haracteristics of the patients were very similar in many aspects
type of AF, association or not with left ventricular systolic
ysfunction, medication during follow-up), although the way of
ollecting a large amount of data was somewhat different.
However, and in contrast to the results presented by Nieuwlaat et
l. (1), we found that in unselected patients with AF and HF,
reatments with beta-blocker alone or with beta-blocker plus digoxin
ere associated with a significant decrease in the risk of death. We
hink this may have some interest because very few studies have been
ublished to date addressing the effect of beta-blockers in HF patients
aving AF. Beyond the older age of the patients and the continuous
ollection of data in our study, we do not have clear explanation for
hese different results. We were somewhat surprised by the listing of
he multivariable determinants of all-cause mortality in patients with
F and HF in the Euro Heart Survey because it appears that a major
leeding is presented as a strong predictor of death during follow-up.
he parameters included in this type of multivariate analysis should
nly include baseline characteristics of the patients. A severe event
uring follow-up is obviously associated with a higher risk of mortal-
ty. Because a history of major bleeding at baseline is not presented, we
re wondering if Nieuwlaat et al. (1) have included a major bleeding
uring follow-up as a predictor of mortality. If this is the case, this
nappropriate way of performing the analysis may have affected the
nal results on the predictors of all-cause mortality.
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aurent Gorin, MD
Service de Cardiologie B.
entre Hospitalier Universitaire Trousseau
7044 Tours
rance
-mail: lfau@med.univ-tours.fr
doi:10.1016/j.jacc.2009.06.061
EFERENCES
. Nieuwlaat R, Eurlings LW, Cleland JG, et al. Atrial fibrillation and
heart failure in cardiology practice: reciprocal impact and combined
management from the perspective of atrial fibrillation: results of the
Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:
1690–8.
. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and
digoxin alone and in combination for management of patients with
atrial fibrillation and heart failure. Am J Cardiol 2009;103:248–54.. Implementation of the International Statistical Classification of Dis-
eases and Related Health Problems, Tenth Revision (ICD-10). Epide-
miol Bull 1997;18:1–4.
eply
e thank Dr. Smit and colleagues and Drs. Fauchier and Gorin for
heir interest in our paper (1) regarding the characteristics, manage-
ent, and prognosis of patients with the combination of atrial
brillation (AF) and heart failure (HF) in the Euro Heart Survey.
First, we would like to clarify that the variable “major bleeding” in
he multivariable analyses concerns a history of major bleeding at
aseline, rather than major bleeding during study follow-up.We want
o congratulate Fauchier et al. (2) on their interesting study showing
mproved survival of patients with AF and HF who receive a
eta-blocker. However, we did not find a benefit of beta-blockers in
ur prospective survey, which was also the case in subanalyses of the
IBIS II (The Cardiac Insufficiency Bisoprolol Study II) (3) and
ERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in
ongestive Heart Failure) (4) trials as pointed out by Dr. Smit and
olleagues. There are multiple potential reasons for these different
esults, among which are study setting, selection of the population,
tudy design, and follow-up duration. Only randomized controlled
rials specifically designed to test the effect of beta-blockers among
hese patients can clarify this issue. The same argument holds for the
ate control target issue as raised by Dr. Smit and colleagues. The AF
uidelines indicate that rhythm versus rate control studies usually used
rate control target of 60 to 80 beats/min and is reasonable (5).
owever, it is unknown whether aiming for80 beats/min produces
uperior therapeutic effects compared with a lower or higher target.
he RACE II (Rate Control Efficacy in Permanent Atrial Fibrilla-
ion) trial (6) will indeed shed more light on this issue for permanent
F patients.
No or inconclusive research evidence can be a reason for subopti-
al implementation of therapies. Until stronger evidence is available,
e will have to rely on guideline recommendations optimally weigh-
ng the evidence as extrapolated from more general trial patient
roups, observational studies such as ours, and expert opinion.
nadequate guideline adherence is a multifactorial problem of which
ack of firm evidence is an important, but not the only, aspect.
ver-growing research evidence will clarify management issues that
re of importance, but implementing this evidence optimally in local
ractice is another issue (7). Understanding the causes for gaps
etween guidelines and practice and finding effective ways to close
hem is an essential next step in the continuous feedback loop between
esearch and practice (8).We hope that our survey and the discussions
y Dr. Smit and colleagues and Drs. Fauchier and Gorin will
timulate further research to improve the care and outcomes for
atients with AF and HF.
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eripheral Blood Monocyte
ubset Assessment in
on–ST-Segment Elevation
yocardial Infarction Is Required
e read with great interest both the research paper by Tsujioka et
l. (1) and the editorial comment by Shantsila and Lip (2)
utlining the role of monocytes in myocardial infarction (MI). We
gree that understanding the role of different monocyte population
ubsets during acute coronary syndromes (ACS) might provide
mportant clinical information; however, much more work is
equired, and there is a need to express some cautionary notes. An
mportant limitation in the paper by Tsujioka et al. (1) and others
eferenced by Shantsila and Lip’s editorial (2) in considering the
inetics of monocyte chemoattractant protein (MCP)-1 release (3)
re the small sample sizes (n  36 and n  23 for MI,
espectively). Thus, interpretation must be restrained. Our data
rom 216 patients with ACS do not support the association of the
arly release kinetics of MCP-1 (the ligand for chemokine [C-C
otif] receptor 2 [CCR-2]). Thus, the idea that it is related to the
prompt up-regulation of CCR-2 expressing CD14CD16-
onocytes” might not be correct (2). In our larger ACS popula-
ion, we found no time-dependent increase in MCP-1 measure-
ent during the first 12 h after the onset of symptoms (4). In
ddition, Tsujioka et al. (1) present data indicating that there was
n increase in the CD14CD16 subgroup (these cells lack dCR-2; refer to Figs. 3B and 4D in Tsujioka et al. [1]) in that at
dmission the levels were lower in the MI group as compared with
he stable angina group, with subsequent peak levels in the MI
roup significantly higher (1). However, this cell subpopulation
id not correlate with myocardial salvage (1). Moreover, the data
re from patients with ST-segment myocardial infarction
STEMI), which tend to be larger infarctions. Data in a more
iverse group, including those with smaller events diagnosed with
ardiac troponin—which is recommended by the guidelines groups
5)—would be important to see whether differences exist between
hose groups (1).
If monocyte subgroups are important in non-STEMI, they
ight prove extremely useful in deciding on the timing of invasive
ntervention. Non-STEMI patients benefit from early intervention
ut not necessarily immediate intervention (6). Perhaps data
elated to monocyte activity and expression would help to differ-
ntiate those who might benefit immediately from those who can
ait for some hours. Such considerations will require detailed
nformation on the effects of invasive interventions on monocyte
ubgroups as well as whether serial monitoring is required for risk
tratification. These are important issues, which when addressed will
hed additional light on the role of monocytes and their laboratory use
n risk stratification for patients presenting with ACS.
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e are grateful to Drs. Kavsak and Jaffe for their valuable
omments and suggestions to our study (1). They pose a
uestion regarding the kinetics of monocyte chemoattractant
rotein (MCP)-1 release. They found no time-dependent
ncrease in MCP-1 measurement during the first 12 h after the
nset of symptoms in 216 patients with acute coronary syn-
romes (2). On the contrary, Matsumori et al. (3) have
